Omeros Corp (OMER)

$10.98 +0.09 (0.87%)
Market Cap 783.68M
Revenue (ttm) 0.00
Net Income (ttm) -3.35M
EPS (ttm) N/A
PE Ratio 6.16
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.72
Volume 1,231,400
Avg Vol 1,054,208
Day's Range N/A - N/A
Shares Out 72.00M
Stochastic %K 37%
Beta 2.53
Analysts Strong Sell
Price Target $43.67

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
rongside
rongside Apr. 8 at 2:08 AM
$OMER As per GD comments at the last quarterly earning report: "For YARTEMLEA, we are evaluating expansion opportunities in additional indications, including acute respiratory distress syndrome or ARDS, solid organ transplant-related TMA and other endothelial injury-related disorders." If solid organ transplant (SOT) patients experiencing TMA can be treated with Yartemlea then it is a blockbuster product by itself: without taking ARDS, long covid, myasthenia gravis etc. into consideration. The market cap reflects both ignorance and manipulation. The market not only ignores multiple early stage platforms with tremendous potential but also chooses to ignore the potential of approved products and partnered platform drugs (MASP-3). The MASP-2 franchise is much larger than most have given it credit for. It will be generating billions in sales. Major regulatory risks are minimal: it is already approved.
1 · Reply
rongside
rongside Apr. 8 at 1:49 AM
$OMER as per AI - "Transplant-associated thrombotic microangiopathy (TA-TMA) in solid organ transplant (SOT) is an under-recognized, serious complication with variable reported incidence, generally ranging from 0.8% to 14% in kidney transplant recipients. While most commonly studied in hematopoietic stem cell transplants, TA-TMA in SOT—particularly renal and liver—is often triggered by calcineurin inhibitors (CNIs), ischemia-reperfusion injury, or infections, and is associated with high graft dysfunction and mortality." Yartemlea is an approved product. It is being quickly accepted by all the major transplant centers. While off label use is not unreasonable, IMO doctors will be clamoring for a trial in SOT patients expressing TMA. Remember that continued use of calcineurin inhibitors is actually possible with Yartemlea. This is huge as it is a prime cause of TMA injury. OMER has been testing this for years. All transplant patients could benefit. https://www.researchgate.net/publication/262683094_Mannan-binding_lectin-associated_serine_protease_2_is_critical_for_the_development_of_renal_ischemia_reperfusion_injury_and_mediates_tissue_injury_in_the_absence_of_complement_C4
1 · Reply
LFG2030
LFG2030 Apr. 7 at 11:41 PM
$BZAI $OMER $AIXI
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 11:39 PM
$OMER https://www.cnn.com/2026/04/07/world/live-news/iran-war-trump-us-israel • JUST IN: President Donald Trump said he’d agreed to a two-week ceasefire with Iran on Tuesday on the condition that Iran agree to reopen the critical Strait of Hormuz. Israel has also agreed to the ceasefire, a White House official said. • Request for diplomacy: Trump’s announcement comes after Pakistani Prime Minister Shehbaz Sharif proposed the ceasefire to allow for diplomatic negotiations between the US and Iran.
0 · Reply
Phase3
Phase3 Apr. 7 at 11:27 PM
$OMER Why don't institutional investors see what we see?
1 · Reply
Phase3
Phase3 Apr. 7 at 11:24 PM
$OMER Cease fire should help...
1 · Reply
mjk49
mjk49 Apr. 7 at 11:10 PM
$OMER We need a big whale sometime soon squeezing this one... Shorts should be torched…
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 10:48 PM
$OMER today's chart too is very interesting heavy buying
0 · Reply
4Reel
4Reel Apr. 7 at 10:46 PM
$OMER market is up significantly ah, and xbi up 1.3%. Should see a considerable move up tomorrow if this holds with algos. Hopefully it holds. Lets recover at least 5% back with the green market, pre and ah don't matter either on a thinly traded tute stock🤙
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 9:59 PM
$OMER THE WHOLE FAMILY OWNS SHARES WIFE KIDS EVERYBODY
1 · Reply
Latest News on OMER
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 31, 2026, 4:02 PM EDT - 7 days ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 26, 2026, 8:45 AM EDT - 12 days ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Mar 21, 2026, 3:23 AM EDT - 17 days ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Feb 17, 2026, 8:45 AM EST - 7 weeks ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 2 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 3 months ago

Omeros prices transplant complication drug at $36,000 per dose

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 26, 2025, 6:36 PM EST - 3 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Gold Edges Lower; Omeros Shares Jump

Dec 24, 2025, 12:21 PM EST - 3 months ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:05 AM EST - 3 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 24, 2025, 9:00 AM EST - 3 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Dec 1, 2025, 8:30 AM EST - 4 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 5 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Nov 11, 2025, 8:30 AM EST - 5 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 16, 2025, 8:30 AM EDT - 6 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Oct 15, 2025, 2:58 PM EDT - 6 months ago

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

NVO

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 11:54 AM EDT - 6 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

Oct 15, 2025, 9:17 AM EDT - 6 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Oct 15, 2025, 8:32 AM EDT - 6 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Oct 15, 2025, 8:30 AM EDT - 6 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Sep 2, 2025, 8:45 AM EDT - 7 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:02 PM EDT - 8 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Aug 11, 2025, 4:02 PM EDT - 8 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jul 25, 2025, 8:00 AM EDT - 9 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 27, 2025, 8:30 AM EDT - 10 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 24, 2025, 8:30 AM EDT - 10 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Jun 10, 2025, 12:53 PM EDT - 10 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 11 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 5:05 PM EDT - 11 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 12, 2025, 10:35 AM EDT - 11 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 1 year ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 28, 2025, 7:39 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 12:28 PM EST - 1 year ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 21, 2024, 9:15 AM EST - 1 year ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Nov 11, 2024, 4:11 PM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Oct 24, 2024, 8:45 AM EDT - 1 year ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

rongside
rongside Apr. 8 at 2:08 AM
$OMER As per GD comments at the last quarterly earning report: "For YARTEMLEA, we are evaluating expansion opportunities in additional indications, including acute respiratory distress syndrome or ARDS, solid organ transplant-related TMA and other endothelial injury-related disorders." If solid organ transplant (SOT) patients experiencing TMA can be treated with Yartemlea then it is a blockbuster product by itself: without taking ARDS, long covid, myasthenia gravis etc. into consideration. The market cap reflects both ignorance and manipulation. The market not only ignores multiple early stage platforms with tremendous potential but also chooses to ignore the potential of approved products and partnered platform drugs (MASP-3). The MASP-2 franchise is much larger than most have given it credit for. It will be generating billions in sales. Major regulatory risks are minimal: it is already approved.
1 · Reply
rongside
rongside Apr. 8 at 1:49 AM
$OMER as per AI - "Transplant-associated thrombotic microangiopathy (TA-TMA) in solid organ transplant (SOT) is an under-recognized, serious complication with variable reported incidence, generally ranging from 0.8% to 14% in kidney transplant recipients. While most commonly studied in hematopoietic stem cell transplants, TA-TMA in SOT—particularly renal and liver—is often triggered by calcineurin inhibitors (CNIs), ischemia-reperfusion injury, or infections, and is associated with high graft dysfunction and mortality." Yartemlea is an approved product. It is being quickly accepted by all the major transplant centers. While off label use is not unreasonable, IMO doctors will be clamoring for a trial in SOT patients expressing TMA. Remember that continued use of calcineurin inhibitors is actually possible with Yartemlea. This is huge as it is a prime cause of TMA injury. OMER has been testing this for years. All transplant patients could benefit. https://www.researchgate.net/publication/262683094_Mannan-binding_lectin-associated_serine_protease_2_is_critical_for_the_development_of_renal_ischemia_reperfusion_injury_and_mediates_tissue_injury_in_the_absence_of_complement_C4
1 · Reply
LFG2030
LFG2030 Apr. 7 at 11:41 PM
$BZAI $OMER $AIXI
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 11:39 PM
$OMER https://www.cnn.com/2026/04/07/world/live-news/iran-war-trump-us-israel • JUST IN: President Donald Trump said he’d agreed to a two-week ceasefire with Iran on Tuesday on the condition that Iran agree to reopen the critical Strait of Hormuz. Israel has also agreed to the ceasefire, a White House official said. • Request for diplomacy: Trump’s announcement comes after Pakistani Prime Minister Shehbaz Sharif proposed the ceasefire to allow for diplomatic negotiations between the US and Iran.
0 · Reply
Phase3
Phase3 Apr. 7 at 11:27 PM
$OMER Why don't institutional investors see what we see?
1 · Reply
Phase3
Phase3 Apr. 7 at 11:24 PM
$OMER Cease fire should help...
1 · Reply
mjk49
mjk49 Apr. 7 at 11:10 PM
$OMER We need a big whale sometime soon squeezing this one... Shorts should be torched…
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 10:48 PM
$OMER today's chart too is very interesting heavy buying
0 · Reply
4Reel
4Reel Apr. 7 at 10:46 PM
$OMER market is up significantly ah, and xbi up 1.3%. Should see a considerable move up tomorrow if this holds with algos. Hopefully it holds. Lets recover at least 5% back with the green market, pre and ah don't matter either on a thinly traded tute stock🤙
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 9:59 PM
$OMER THE WHOLE FAMILY OWNS SHARES WIFE KIDS EVERYBODY
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 6:23 PM
$OMER and $IBRX TWO HOPE FOR HUMANITY AGAINST COVID https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-reports-narsoplimab-treatment-results Reduction in Mortality Risk with Narsoplimab -- SEATTLE--(BUSINESS WIRE)--Sep. 15, 2022-- Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR <1] equal to 0.77). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial.
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 6:18 PM
$OMER two biggest names in the business omer and $IBRX FIGHTING THE GOOD FIGHT
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 5:36 PM
$OMER yes!!
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 5:30 PM
$OMER ceo needs to update on today's eu meeting https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-april-2026_en.pdf
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 5:18 PM
$OMER only way you do a 2 billion dollar deal with a big $NVO and keep your COMPANY HAS TO BE BECAUSE YOU'RE WORTH WAY MORE $MRNA $PFE Licensing deal https://www.globenewswire.com/news-release/2025/10/15/3167091/0/en/Novo-Nordisk-and-Omeros-announce-asset-purchase-and-license-agreement-for-Omeros-clinical-stage-MASP-3-inhibitor-zaltenibart-OMS906.html Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 4:46 PM
People would be happy if $OMER did a 2 billion dollar deal and sold the company like$SLNO . They did the 2 billion dollar deal and kept the company with 240 million upfront cash to $NVO. THIS OS THEIR THIRD DRUG FDA APPROVAL FIRST FRANCHISED OUT EATING OFF THAT TOO +5 Narsoplimab-wuug (brand name Yartemlea), approved by the FDA in December 2025, is a first-in-class, fully human monoclonal antibody for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged 2 years and older. It acts as a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor, stopping the complement pathway activation. OncotoX-AML is an engineered biologic designed by Omeros Corporation to selectively destroy acute myeloid leukemia (AML) blasts and relapse-related stem cells, independent of common genetic mutations. Preclinical studies show it surpasses current standards (VenAza) by causing up to 99% reduction in leukemic cells
0 · Reply
SignalStudioOutlook
SignalStudioOutlook Apr. 7 at 4:16 PM
$OMER biotech company Omeros.
0 · Reply
SignalStudioOutlook
SignalStudioOutlook Apr. 7 at 3:56 PM
$OMER biotech company Omeros.
0 · Reply
capntrps
capntrps Apr. 7 at 3:54 PM
$OMER im sticking w this dogshit is annoying. Bought some at 10 and sold at profit in the last week or so. Will do again if necessary. Could switch stock for options, but i havent liked the premiums so far. Who knows...
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 3:51 PM
$OMER per article mid year Omeros Corporation has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab has orphan drug designation, with a CHMP opinion expected by mid-2026. Status: The MAA for narsoplimab is currently under review by the EMA following submission in mid-2025. Indication: Treatment of high-mortality TA-TMA, a complication of hematopoietic stem cell transplants. Designation: The EMA granted orphan drug designation, which enables a centralized review process across all EU member states, Iceland, Liechtenstein, and Norway. Timeline: The review process, involving the Committee for Medicinal Products for Human Use (CHMP), began in mid-July 2025, with a final decision anticipated in mid-2026.
0 · Reply
Tyler1100
Tyler1100 Apr. 7 at 3:46 PM
$OMER if they're meeting today when is their finding supposed to be, today? Or just meeting to discuss? Looked at website and sats meeting from april 7 to 10? Not sure im understanding
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 7 at 3:35 PM
$OMER 5:33 pm in amersterdam let's see if we get that update https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-april-2026_en.pdf
0 · Reply